Jiangsu Hengrui Medicine Co., Ltd (SHA: 600276), a leading Chinese pharmaceutical company, has received approval from the National Medical Products Administration (NMPA) to initiate a Phase II clinical trial for its investigational drug SHR7280, aimed at treating heavy menstrual bleeding associated with uterine fibroids.
SHR7280 is an oral small molecule GnRH receptor antagonist designed to inhibit the binding of endogenous GnRH to its receptors, thereby suppressing the synthesis and release of luteinizing hormones, follicle-stimulating hormones, and other gonadotropins. This drug is being developed specifically for the treatment of uterine fibroids and endometriosis, with no comparable products currently approved for marketing in China.- Flcube.com
